Intuitive delivered the cleanest proof point of the da Vinci refresh cycle in the second quarter. Procedures grew faster than installed base, instrument revenue outgrew placements, and operating margin expanded even as research and development spending ran heavier, an atypical combination for a company already at scale. The story of the quarter is not the headline number but the composition underneath it: da Vinci 5 placements accelerated, the recurring consumables line crossed the eighteen percent growth band, and the Ion biopsy franchise compounded at a rate that would itself justify a separate equity if it were standalone. The closure of the European distribution acquisitions also converted what had been a slow-motion headwind on procedure mix into a clean direct-to-customer revenue path.
The valuation context frames why the operating print matters more than usual. Shares trade near $369 against a fifty-two-week range that brackets the lows and highs of the past year, with a market capitalization of roughly $132B and a forward earnings multiple near thirty-one times consensus. The market is paying for procedure compounding, not for the legacy hardware franchise, and the print this quarter validated that distinction: recurring revenue reached $2.47B and represented eighty-five percent of total, a figure that defines what kind of business Intuitive has become. Procedure growth of fifteen percent on a base of nearly 11,710 installed systems, combined with rising instruments and accessories revenue per procedure, is the math behind the multiple, and this quarter's print put a quarter's worth of new evidence behind it.
The strongest counterargument sits in the operating margin expansion. Operating income grew thirty-one percent, well above the nineteen percent revenue pace, and a portion of that lift came from a benign tax rate comparison and intangible amortization that compares against a small prior-year base. Stripping those one-time tailwinds, the durable margin expansion narrows but does not disappear, and the deeper read is that the recurring-revenue mix is structurally lifting gross profit even as the cost base grows. The variable that determines whether the multiple is justified is whether the da Vinci 5 refresh cycle continues to translate into higher instruments and accessories revenue per procedure without requiring further pricing concessions in markets like China, where the National Healthcare Security Administration has begun to shape the reimbursement regime for robotic-assisted surgery.